<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13422">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02090907</url>
  </required_header>
  <id_info>
    <org_study_id>392349</org_study_id>
    <nct_id>NCT02090907</nct_id>
  </id_info>
  <brief_title>Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism</brief_title>
  <official_title>Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothyroidism is risk factor in atherosclerotic cardiovascular diseases, but there is a
      controversy in effect of subclinical hypothyroidism on cardiovascular diseases. We aim to
      estimate the relation between subclinical hypothyroidism and endothelial dysfunction and the
      effects of levothyroxine therapy on it. Patients with confirmed subclinical hypothyroidism
      by lab results will be randomized to two groups of treatment with one daily dose of 100 mg
      Levothyroxine or placebo. The flow-mediated dilation and intima media thickness are
      evaluated before and after the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline flow-mediated dilation at 2 months</measure>
    <time_frame>At baseline and then 2 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Flow-mediated dilation will be assessed using standard method with a radiologist unaware to the study arms at baseline and then 2 months after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline intima-media thickness at 2 months</measure>
    <time_frame>At baseline and then 2 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Intima-media thickness will be assessed using standard method with a radiologist unaware to the study arms at baseline and then 2 months after treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Subclinical Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>Levothyroxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the treatment group, daily doses of 100 mg of Levothyroxine will be administered every morning, half an hour before breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the placebo group treatment regimen and advices are identical to that of the treatment group, except for using a pharmacologically neutral agent, with complete resemblance to the real treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine</intervention_name>
    <arm_group_label>Levothyroxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 to 65

          -  confirmed subclinical hypothyroidism

        Exclusion Criteria:

          -  receiving of other treatments for hypothyroidism

          -  patients with other major medical disorders

          -  smoking

          -  hyperlipidemia

          -  obesity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nasmi Niknam, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isfahan University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Khorshid endocrinology clinic</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, Michelangeli V. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005 Nov 28;165(21):2467-72.</citation>
    <PMID>16314542</PMID>
  </reference>
  <reference>
    <citation>Alibaz Oner F, Yurdakul S, Oner E, Kubat Uzum A, Erguney M. Evaluation of the effect of L-thyroxin therapy on endothelial functions in patients with subclinical hypothyroidism. Endocrine. 2011 Oct;40(2):280-4. doi: 10.1007/s12020-011-9465-2. Epub 2011 Apr 20.</citation>
    <PMID>21505892</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Isfahan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Nasmi Niknam</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Subclinical hypothyroidism</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Prevention</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
